JonesTrading has initiated coverage on shares of Evaxion A/S (NASDAQ: EVAX) with a buy rating and a price target of $10.00. This announcement was made in a research report published on the morning of March 5, 2024, according to a report by Benzinga. The positive outlook from JonesTrading aligns with a generally favorable sentiment among other research analysts regarding the company.
Multiple analysts have recently weighed in on Evaxion’s stock. For instance, Lake Street Capital revised its price target from $11.00 to $9.00 while maintaining a buy rating. Similarly, the Maxim Group initiated coverage on February 19, 2024, also giving the stock a buy rating and a target price of $10.00. Notably, HC Wainwright reaffirmed a buy rating with a target price of $16.00. In contrast, Weiss Ratings issued a “sell” rating with a grade of D- on January 9, 2024. Currently, five analysts have rated the stock as a buy, while one has issued a sell rating, leading to an average rating of “Moderate Buy” and an average target price of $11.00, according to MarketBeat.com.
Recent Financial Performance and Investor Activity
Evaxion A/S recently reported its quarterly earnings on March 5, 2024, indicating earnings per share (EPS) of $0.30. As for the ongoing financial year, analysts project a loss with an expected EPS of -0.15.
In terms of institutional investment, several hedge funds and institutional investors have adjusted their holdings in Evaxion. Wesbanco Bank Inc. acquired a new stake valued at $48,000, while Northwestern Mutual Wealth Management Co. purchased shares worth $38,000. Additionally, SmartHarvest Portfolios LLC bought a position valued at $72,000. Collectively, institutional investors hold approximately 11.04% of the company’s stock.
About Evaxion A/S
Headquartered in Copenhagen, Denmark, Evaxion A/S is a clinical-stage biotechnology company that focuses on developing immunotherapies and vaccines. The firm leverages its proprietary AI-based computational immunology platform to create innovative solutions for both therapeutic cancer vaccines and preventive vaccines for infectious diseases. By utilizing machine learning and deep learning techniques, Evaxion aims to identify and optimize antigen targets effectively.
The company’s AI platform processes extensive datasets of genomic, proteomic, and immunological information to predict immune-stimulating epitopes. This cutting-edge approach positions Evaxion as a forward-thinking player in the biotechnology sector, with significant potential for growth and impact in the medical field.
Investors and analysts alike will be closely monitoring Evaxion’s progress as it continues to navigate its clinical trials and market presence.
